ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
48 announcements with these filters
AstraZeneca Pharma India will hold its 47th Annual General Meeting on August 10, 2026, via video conferencing to transact ordinary and special business.
AstraZeneca Pharma India received CDSCO approval to market Benralizumab (Fasenra) for treating Hypereosinophilic Syndrome. This regulatory clearance expands the drug's therapeutic indications in the Indian market.
AstraZeneca Pharma India appointed three new Senior Management Personnel effective Aug-Sep 2026. This strengthens leadership in Commercial, Oncology, and Rare Diseases units.
AstraZeneca Pharma India Ltd appointed Mr. Praveen K Mittal as Director – Corporate Affairs effective July 6 2026. The appointment strengthens the company’s corporate affairs and policy engagement.
AstraZeneca Pharma India Ltd announced the resignations of its Business Unit Director – Oncology and its Site Lead, Operations. The company will seek replacements to maintain continuity.
AstraZeneca Pharma received CDSCO approval to market Enhertu for an additional breast cancer indication in India. This regulatory milestone expands the drug's therapeutic reach and commercial potential.
AstraZeneca Pharma received a tax appeal order upholding adjustments worth ₹9.24 Crore for FY 2018-19. The company plans to challenge the order before the GST Appellate Tribunal.
AstraZeneca Pharma India Limited surrendered its factory license following its manufacturing site exit. This administrative move marks the final phase of closing its domestic production facility.
AstraZeneca Pharma India announced the resignations of senior executives Mr. Ayush Kumar Agarwal and Ms. Shikha Mirchandani Chatrath. The company is seeking suitable replacements.
AstraZeneca Pharma India Limited filed its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report confirms overall regulatory compliance with no new penalties.
AstraZeneca Pharma India appointed Ms. Shilpa Divekar Nirula as Chairperson for five years. BSR & Co. LLP was also appointed as Statutory Auditor for a 60-month term.
AstraZeneca Pharma India recommended a final dividend of ₹24 per equity share for FY 2025-26. The payout is subject to shareholder approval at the August AGM.
AstraZeneca Pharma India reported FY 2025-26 revenue of ₹2,275.58 Crore, marking 33% growth. The Company secured 11 regulatory approvals, reinforcing leadership in oncology and biopharmaceuticals.
AstraZeneca Pharma India Ltd reported revenue from operations of ₹578.6 Cr (+20.4% YoY) and net profit of ₹44.9 Cr (-22.9% YoY) for Q4 FY26.
AstraZeneca Pharma India reported ₹2,275.58 Crore total income for FY25-26, marking 33% growth. The board recommended a ₹36 per share dividend, reflecting strong performance.
AstraZeneca Pharma India received CDSCO approval to market Calquence for treating previously untreated mantle cell lymphoma. This expands the drug's Indian market indications for adult patients.
AstraZeneca Pharma India updated its list of Key Managerial Personnel authorized to determine event materiality. This administrative disclosure ensures compliance with SEBI Listing Obligations.
AstraZeneca Pharma India scheduled a board meeting for May 26, 2026. Directors will consider FY26 audited financial results and potential dividend recommendations for shareholders.